These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21334762)

  • 1. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B].
    Suárez E; Gila A; Figueruela B; Chueca N; Muñoz Rueda P; Puche B; Fraga E; García F; Martín JM; Andrade RJ; Nogales C; Romero-Gómez M; Salmerón J
    Gastroenterol Hepatol; 2011 Feb; 34(2):69-74. PubMed ID: 21334762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
    Jung HW; Choi MS; Kim KH; Park SH; Yeon KK; Lee JH; Koh KC; Paik SW; Yoo BC
    Korean J Hepatol; 2009 Mar; 15(1):52-8. PubMed ID: 19346785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.
    van der Poorten D; Prakoso E; Khoo TL; Ngu MC; McCaughan GW; Strasser SI; Lee AU
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1500-5. PubMed ID: 17683493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
    Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.